Vaxart Inc. (VXRT) gained after-hours following the release of positive results from a study that showed its oral tablet vaccine reduced the spread of SARS-CoV-2 in an animal model. VXRT stock surges over 9% in the pre-market session. It is trading at $7.77 today. Vaxart said that the results of its Phase 2 human flu challenge study are consistent with those from its Phase 2 study, which showed that its oral tablet vaccine was better than the injectable flu vaccine.
Vaxart said that its oral vaccine platform has the potential to trigger a broad and robust mucosal response in humans. The results of the study indicate that Vaxart’s oral vaccine could provide better protection against respiratory viruses than conventional vaccines. Vaxart is a biotechnology company focused on the development of vaccines for the protection of people against various infectious diseases. Vaxart has traded between $24.90 and $7.87 over the past 52 weeks. In late-hours trading on Thursday, the stock gained 11%.